Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

176.36USD
1:30am IST
Change (% chg)

$-1.11 (-0.63%)
Prev Close
$177.47
Open
$177.10
Day's High
$177.54
Day's Low
$174.91
Volume
1,193,919
Avg. Vol
1,289,741
52-wk High
$210.18
52-wk Low
$165.23

Select another date:

Tue, Apr 16 2019

Photo

Amgen sets $21,900 annual price for new Evenity bone drug

Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.

Amgen sets $21,900 annual price for new Evenity bone drug

April 15 Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.

Amgen's postmenopausal osteoporosis drug gets FDA greenlight

The U.S. Food and Drug Administration said on Tuesday it had approved Amgen Inc's osteoporosis treatment for postmenopausal women who are at high risk of fracture.

Amgen's postmenopausal osteoporosis drug gets FDA greenlight

The U.S. Food and Drug Administration said on Tuesday it had approved Amgen Inc's osteoporosis treatment for postmenopausal women who are at high risk of fracture.

UPDATE 2-Amgen's postmenopausal osteoporosis drug gets FDA greenlight

April 9 The U.S. Food and Drug Administration said on Tuesday it had approved Amgen Inc's osteoporosis treatment for postmenopausal women who are at high risk of fracture.

Amgen's postmenopausal osteoporosis drug gets FDA approval

April 9 The U.S. Food and Drug Administration on Tuesday approved Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture, according to the regulator's website.

Novartis, Amgen in dispute over migraine drug partnership

NEW YORK/LOS ANGELES Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.

UPDATE 3-Novartis, Amgen in dispute over migraine drug partnership

NEW YORK/LOS ANGELES, April 4 Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.

Novartis sues Amgen over migraine treatment Aimovig

NEW YORK, April 4 Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotech of trying to back out of the companies' agreements to develop and market Aimovig for the prevention of migraines.

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

Select another date: